PMID- 27775635
OWN - NLM
STAT- MEDLINE
DCOM- 20170731
LR  - 20221207
IS  - 1660-4601 (Electronic)
IS  - 1661-7827 (Print)
IS  - 1660-4601 (Linking)
VI  - 13
IP  - 10
DP  - 2016 Oct 20
TI  - Polymorphisms of HLA-DM on Treatment Response to Interferon/Ribavirin in Patients 
      with Chronic Hepatitis C Virus Type 1 Infection.
LID - 1030
AB  - BACKGROUND: HLA-DM gene, which is related to antigen processing and presentation 
      and located in the non-classical class-II region of human leukocyte antigen (HLA) 
      region, may play a crucial role in chronic hepatitis C virus (HCV) infection 
      treatment outcomes. The study was conducted to evaluate the role of the variant 
      of several single nucleotide polymorphisms (SNPs) in HLA-DM gene in HCV treatment 
      outcomes. METHODS: We genotyped four SNPs from the candidate genes (HLA-DMA and 
      DMB) in 336 patients who were treated with pegylated interferon-alpha and 
      ribavirin (PEG IFN-alpha/RBV). Multivariate analysis of factors predicting sustained 
      virological response (SVR) was conducted. RESULTS: HLA-DMA rs1063478 and DMB 
      rs23544 were independent factors of HCV treatment outcomes in Chinese Han 
      population. Individuals who carried favorable genotypes of rs1063478TT and 
      rs23544GG were more likely to achieve SVR Dominant model: odds ratio (OR) = 
      2.05, 95% confidence interval (CI) = 1.24-3.41; OR = 2.04, 95% CI =1.23-3.35, 
      respectively. Rs23544, rs1063478, baseline glucose, baseline platelet and T4 
      level were independent predictors of SVR. The area under the receiver operating 
      characteristic (ROC) curve (AUC) was 0.740. CONCLUSIONS: The genetic variation of 
      rs1063478 and rs23544 are associated with the treatment outcomes in the Chinese 
      Han population.
FAU - Chen, Hongbo
AU  - Chen H
AD  - Department of Infectious Disease, the Jurong People's Hospital, Jurong 212400, 
      China. chb2180@126.com.
FAU - Yao, Yinan
AU  - Yao Y
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Nanjing 
      Medical University, Nanjing 211166, China. yinanyao1130@163.com.
FAU - Wang, Yifan
AU  - Wang Y
AD  - Department of Infectious Disease, the Jurong People's Hospital, Jurong 212400, 
      China. yifanwang333@163.com.
FAU - Zhou, Hua
AU  - Zhou H
AD  - Department of Infectious Disease, the Jurong People's Hospital, Jurong 212400, 
      China. huazhou4456@163.com.
FAU - Xu, Tianxiang
AU  - Xu T
AD  - Department of Infectious Disease, the Jurong People's Hospital, Jurong 212400, 
      China. xutianq@163.com.
FAU - Liu, Jing
AU  - Liu J
AD  - Department of Infectious Disease, the Jurong People's Hospital, Jurong 212400, 
      China. xyxJ6300@sina.com.
FAU - Wang, Guocheng
AU  - Wang G
AD  - Department of Infectious Disease, the Jurong People's Hospital, Jurong 212400, 
      China. guochengwang4456@163.com.
FAU - Zhang, Yongfeng
AU  - Zhang Y
AD  - Department of Infectious Disease, the Jurong People's Hospital, Jurong 212400, 
      China. yongfengzhang666@163.com.
FAU - Chen, Xiang
AU  - Chen X
AD  - Department of Infectious Disease, the Jurong People's Hospital, Jurong 212400, 
      China. xiangchen322@163.com.
FAU - Liu, Qingwei
AU  - Liu Q
AD  - Department of Infectious Disease, the Jurong People's Hospital, Jurong 212400, 
      China. lin553210@163.com.
FAU - Huang, Peng
AU  - Huang P
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Nanjing 
      Medical University, Nanjing 211166, China. huangpeng@njmu.edu.cn.
FAU - Yu, Rongbin
AU  - Yu R
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Nanjing 
      Medical University, Nanjing 211166, China. rongbinyu@njmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20161020
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
RN  - 0 (Antiviral Agents)
RN  - 0 (HLA-D Antigens)
RN  - 0 (HLA-DM antigens)
RN  - 0 (Interferon-alpha)
RN  - 49717AWG6K (Ribavirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antiviral Agents/immunology/*therapeutic use
MH  - Asian People/*genetics
MH  - China
MH  - Drug Therapy, Combination
MH  - Female
MH  - Genotype
MH  - HLA-D Antigens/*genetics/immunology
MH  - Hepatitis C, Chronic/*genetics/immunology/*therapy
MH  - Humans
MH  - Interferon-alpha/immunology/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Polymorphism, Single Nucleotide
MH  - Ribavirin/*therapeutic use
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC5086769
OTO - NOTNLM
OT  - HLA-DM gene
OT  - genetic polymorphism
OT  - hepatitis C
OT  - treatment outcome
COIS- The authors declare no conflict of interest. The founding sponsors had no role in 
      the design of the study; in the collection, analyses or interpretation of data, 
      in the writing of the manuscript, and in the decision to publish the results.
EDAT- 2016/10/25 06:00
MHDA- 2017/08/02 06:00
PMCR- 2016/10/01
CRDT- 2016/10/25 06:00
PHST- 2016/07/28 00:00 [received]
PHST- 2016/09/29 00:00 [revised]
PHST- 2016/10/13 00:00 [accepted]
PHST- 2016/10/25 06:00 [pubmed]
PHST- 2017/08/02 06:00 [medline]
PHST- 2016/10/25 06:00 [entrez]
PHST- 2016/10/01 00:00 [pmc-release]
AID - ijerph13101030 [pii]
AID - ijerph-13-01030 [pii]
AID - 10.3390/ijerph13101030 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2016 Oct 20;13(10):1030. doi: 
      10.3390/ijerph13101030.